J&J Medical Connect

Oncology Hematology Areas of Interest

Oncology Hematology Areas of Interest

Compounds with areas of interest for Externally Sponsored Research are listed below. We aren’t accepting proposals at this time for the non-listed compounds.

Submissions are aligned to quarterly portal cut‑offs, with applications reviewed by intake cycle.

 

Brand or Substance Submissions being Considered Areas of Interest Out of Scope
CARVYKTI® (ciltacabtagene autoleucel) Commercial supply only
  • Adverse event (e.g. NTX, colitis, SPM, prolonged cytopenia, infections) management/mitigation measures
  • Registries
  • Effectiveness of potential mitigation measures
  • Mechanism of potential mitigation measures
  • Real world evidence for cilta-cel in early lines RRMM (effectiveness, safety, special populations etc.)
  • Select MoA and biomarkers of efficacy and safety - correlates of response/resistance as well as toxicity
  • Sequencing and washout strategies not involving other J&J assets
  • Bridging and holding therapies not involving other J&J assets
  • Interventional studies requiring cilta-cel supply
  • Research proposals outside of myeloma/plasma cell disorders
  • Duplication of ongoing, planned, published, or collaborative studies
  • MAF study supportive of any other CAR-T
  • Head-to-head studies with competitors

Click here to make a submission

 

Brand or Substance Submissions being Considered Areas of Interest Out of Scope
DARZALEX® (daratumumab)

In scope: Drug and Funding support

Out of scope: Drug only

  • Daratumumab retreatment
  • D-VRd (full dose or lite) in frail NDMM (interventional or real-world)
  • Real-world studies in HR SMM
  • Combinations with JNJ bi-/tri-specific Abs
  • Combinations with CeLMODs
  • Daratumumab monotherapy maintenance
  • Head-to-head treatment comparisons vs competitor therapies
  • Alternate dose or dosing schedules
  • Studies in disease states other than plasma cell disorders

Click here to make a submission

 

Brand or Substance Submissions being Considered Areas of Interest Out of Scope
Ramantamig

In scope: Drug and Funding support

Out of scope: Drug only

  • Ram or ram-dara
  • Special populations (HR, EMD, frail, etc)
  • Combinations with CeLMODs in HR pts
  • Ram after prior bispecific or CAR-T
  • Response (sustained MRD-) adapted Rx
  • Retreatment
  • Head-to-head treatment comparisons vs other TCEs
  • Alternate dose or dosing schedules
  • Studies in disease states other than plasma cell disorders

Click here to make a submission

 

Brand or Substance Submissions being Considered Areas of Interest Out of Scope
TALVEY® (talquetamab-tgvs)

In scope: Drug and Funding support

Out of scope: Drug only

  • Tal-dara combination in dara exposed patients (interventional or real-world)
  • Tec-tal combination in HR (cytogenetic, functional, EMD, etc) patients
  • Combinations with IMiDs or CeLMODs
  • AE mitigation strategies (especially oral)
  • Sequencing (especially Tal before BCMA)
  • Tal retreatment
  • Head-to-head treatment comparisons vs other TCEs
  • Alternate dose or dosing schedules
  • Studies in disease states other than plasma cell disorders

Click here to make a submission

 

Brand or Substance Submissions being Considered Areas of Interest Out of Scope
TECVAYLI® (teclistamab-cqyv)

In scope: Drug and Funding support

Out of scope: Drug only
  • Tec-dara combination in dara exposed patients (interventional or real-world)
  • Tec-tal combination in HR (cytogenetic, functional, EMD, etc) patients
  • Combinations with IMiDs or CeLMODs
  • Infection mitigation strategies
  • Tec retreatment
  • Head-to-head treatment comparisons vs other TCEs
  • Alternate dose or dosing schedules
  • Studies in disease states other than plasma cell disorders

Click here to make a submission

 

Partnerships

Make a submission

Continue
Publications

How to use the system

Continue
J&J Medical Connect

Connect with us

Connect with us